HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients.

AbstractBACKGROUND:
Growth differentiation factor-15 (GDF-15) is a stress-responsive cytokine linked to obesity comorbidities such as cardiovascular disease, inflammation, and cancer. GDF-15 also has adipokine properties and recently emerged as a prognostic biomarker for cardiovascular events.
METHODS:
We evaluated the relationship of plasma GDF-15 concentrations with parameters of obesity, inflammation, and glucose and lipid metabolism in a cohort of 118 morbidly obese patients [mean (SD) age 37.2 (12) years, 89 females, 29 males] and 30 age- and sex-matched healthy lean individuals. All study participants underwent a 75-g oral glucose tolerance test; 28 patients were studied before and 1 year after Roux-en-Y gastric bypass surgery.
RESULTS:
Obese individuals displayed increased plasma GDF-15 concentrations (P < 0.001), with highest concentrations observed in patients with type 2 diabetes. GDF-15 was positively correlated with age, waist-to-height ratio, mean arterial blood pressure, triglycerides, creatinine, glucose, insulin, C-peptide, hemoglobin A(1c), and homeostatic model assessment insulin resistance index and negatively correlated with oral glucose insulin sensitivity. Age, homeostatic model assessment index, oral glucose insulin sensitivity, and creatinine were independent predictors of GDF-15 concentrations. Roux-en-Y gastric bypass led to a significant reduction in weight, leptin, insulin, and insulin resistance, but further increased GDF-15 concentrations (P < 0.001).
CONCLUSIONS:
The associations between circulating GDF-15 concentrations and age, insulin resistance, and creatinine might account for the additional cardiovascular predictive information of GDF-15 compared to traditional risk factors. Nevertheless, GDF-15 changes following bariatric surgery suggest an indirect relationship between GDF-15 and insulin resistance. The clinical utility of GDF-15 as a biomarker might be limited until the pathways directly controlling GDF-15 concentrations are better understood.
AuthorsGreisa Vila, Michaela Riedl, Christian Anderwald, Michael Resl, Ammon Handisurya, Martin Clodi, Gerhard Prager, Bernhard Ludvik, Michael Krebs, Anton Luger
JournalClinical chemistry (Clin Chem) Vol. 57 Issue 2 Pg. 309-16 (Feb 2011) ISSN: 1530-8561 [Electronic] England
PMID21164037 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Growth Differentiation Factor 15
  • Creatinine
  • Glucose
Topics
  • Adult
  • Biomarkers (blood)
  • Blood Pressure
  • Body Weights and Measures
  • Cardiovascular System (metabolism)
  • Creatinine (blood)
  • Diabetes Mellitus, Type 2 (blood, complications)
  • Female
  • Gastric Bypass
  • Glucose (metabolism)
  • Growth Differentiation Factor 15 (blood)
  • Humans
  • Inflammation (blood)
  • Insulin Resistance
  • Kidney Function Tests
  • Lipid Metabolism
  • Male
  • Obesity, Morbid (blood, complications, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: